ATH 33.3% 0.4¢ alterity therapeutics limited

I'm a little confused. Bruno is saying ' the mean atrophy rate...

  1. 221 Posts.
    lightbulb Created with Sketch. 90
    I'm a little confused. Bruno is saying ' the mean atrophy rate observed in the placebo group is in the upper range of what one would expect in mild AD subjects (Kaye et al., 2005). ' That's based on a 35% reduction level.

    Your saying that the results were 45% below AIBL longitudinal results.

    So the line up would be PBT2 -2.6%, Placebo -4%, AIBL -4.7%. The AIBL longitudinal result is further away from the upper range of what one would expect in mild AD subjects (according to Bruno and Kaye)?

    Am I missing something?
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.